Results 101 to 110 of about 592,133 (314)

Boost and Increased Antibody Breadth Following a Second Dose of PARVAX for SARS-CoV-2 in Mice and Nonhuman Primates

open access: yesVaccines
PARVAX is a genetic vaccine platform based on an adeno-associated vector that has demonstrated to elicit potent, durable, and protective immunity in nonhuman primates (NHPs) after a single dose. Here, we assessed vaccine immunogenicity following a PARVAX
Urja Bhatt   +15 more
doaj   +1 more source

A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate

open access: yesFrontiers in Oncology, 2019
For patients with unfavorable or high-risk prostate cancer, dose escalated radiation therapy leads to improved progression free survival but attempts to deliver increased dose by external beam radiation therapy (EBRT) alone can be limited by late ...
Benjamin W. Fischer-Valuck   +4 more
doaj   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim   +17 more
wiley   +1 more source

Conversores CC-CC básicos não-isolados quadráticos de três níveis [PDF]

open access: yes, 2006
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro Tecnológico. Programa de Pós-Graduação em Engenharia Elétrica.Este trabalho introduz uma nova célula de comutação formada por dois diodos, dois interruptores comandados, dois ...
Bottarelli, Marlos Gatti
core  

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

open access: yesMolecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim   +11 more
wiley   +1 more source

A Zero Input Current Ripple ZVS/ZCS Boost Converter with Boundary-Mode Control

open access: yesEnergies, 2014
In this paper, in order to achieve zero ripple conditions, the use of a ripple mirror (RM) circuit for the boost converter is proposed. The operation modes are studied and steady-state analyses performed to show the merits of the proposed converter.
Ching-Ming Lai   +2 more
doaj   +1 more source

scikit-hep/boost-histogram: Version 1.0.2

open access: yes, 2021
Dropped support for Python 2 and 3.5; removed large numbers of workarounds. Fully statically typed. API compatible with the final 0.x release for most uses, except for subclassing; subclassing histogram components now uses Python 3 class keyword syntax ...
Doug Davis   +8 more
core   +1 more source

The impact of leukocyte‐associated RNA retention on platelet RNA‐based cancer detection

open access: yesMolecular Oncology, EarlyView.
Platelets carry RNA signals that may help detect cancer, but platelet samples can also retain RNA from white blood cells. We found that this retained white blood cell signal did not significantly affect machine learning cancer classification, suggesting that the cancer‐related RNA signal in platelets is largely independent of leukocyte‐associated RNA ...
Michał Sieczczyński   +12 more
wiley   +1 more source

Ultra-Hypofractionated Radiotherapy Plus Boost for T1-2 Breast Cancer Patients: Early Results of a Prospective Study Based on the Fast-Forward Scheme

open access: yesEuropean Journal of Breast Health
Objective: Hypofractionated radiotherapy (RT) is the standard adjuvant treatment for breast cancer patients after surgery. The recent results of the FAST-FORWARD trial on ultra-hypofractionated RT, delivered over one week, support a viable alternative ...
Efrosyni Kypraiou   +8 more
doaj   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

open access: yesMolecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy